Results 11 to 20 of about 256,425 (387)

Preparation and Evaluation of 6-Gingerol Derivatives as Novel Antioxidants and Antiplatelet Agents

open access: yesAntioxidants, 2023
Ginger (Zingiber officinale) is widely used as a spice and a traditional medicine. Many bioactivities have been reported for its extracts and the isolated compounds, including cardiovascular protective effects.
Sara H. H. Ahmed   +9 more
doaj   +1 more source

Percutaneous coronary intervention with drug‐coated balloon‐only strategy combined with single antiplatelet treatment in patients at high bleeding risk: Single center experience of a novel concept

open access: yesCatheterization and cardiovascular interventions, 2023
At least 1 month of dual antiplatelet therapy is required after coronary stenting. The aim of this all‐comers retrospective registry study was to assess the efficacy and safety of percutaneous coronary intervention (PCI) using drug‐coated balloon (DCB ...
Alma Räsänen   +4 more
semanticscholar   +1 more source

Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases

open access: yesPlatelets, 2021
Antiplatelet medications comprise the cornerstone of treatment for diseases that involve arterial thrombosis, including acute coronary syndromes (ACS), stroke and peripheral arterial disease.
Maan H. Harbi   +4 more
doaj   +1 more source

Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease

open access: yesBiomedicines, 2021
The successful treatment of peripheral arterial disease (PAD) depends on adequate adherence to medications including antiplatelet agents. The aims of this study were (a) to identify the proportion of nonpersistent patients who reinitiated antiplatelet ...
Martin Wawruch   +8 more
doaj   +1 more source

Myricetin, the main flavonoid in Syzygium cumini leaf, is a novel inhibitor of platelet thiol isomerases PDI and ERp5 [PDF]

open access: yes, 2020
Background: Flavonoids have been characterized as a prominent class of compounds to treat thrombotic diseases through the inhibition of thiol isomerases. Syzygium cumini is a flavonoid-rich medicinal plant that contains myricetin and gallic acid.
Ayyanar   +45 more
core   +1 more source

Sex differences in antiplatelet therapy: state-of-the art

open access: yesPlatelets, 2023
Antiplatelet therapy is a cornerstone of secondary prevention of cardiovascular diseases (CVDs). However, current guidelines are based on data derived primarily from men, as women are generally underrepresented in trials.
A. Gąsecka, J. Zimodro, Y. Appelman
semanticscholar   +1 more source

Antiplatelet therapy after percutaneous coronary intervention.

open access: yesEuroIntervention, 2022
Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI), but it is inevitably associated with increased bleeding.
D. Angiolillo   +4 more
semanticscholar   +1 more source

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial [PDF]

open access: yes, 2019
Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy.
Abano, Nenette   +966 more
core   +5 more sources

Outcomes in Antiplatelet‐Associated Intracerebral Hemorrhage in the TICH‐2 Randomized Controlled Trial

open access: yesJournal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect on functional outcome is uncertain.
ZheKang Law   +21 more
semanticscholar   +1 more source

To clot, or not to clot – Antithrombotic therapy is the question

open access: yesSouth African Family Practice, 2019
Haemostasis and thrombosis rely on three components namely the vascular endothelial wall, blood platelets and the coagulation cascade. Non-physiologic excessive thrombosis occurs when haemostatic processes are dysfunctional, causing undue clot formation ...
E. Osuch, A. Marais
doaj   +1 more source

Home - About - Disclaimer - Privacy